Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auxilium Pharmaceuticals, a specialty biopharmaceutical company, and Ferring International, a Swiss-based pharmaceutical company, have signed an exclusive agreement for the European distribution and license rights to Testim, a proprietary, topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism.
Subscribe to our email newsletter
Under the agreement, Auxilium will be responsible for manufacturing and supplying Testim to Ferring, while Ferring will be responsible for all regulatory, sales, marketing and distribution activities in Europe. Auxilium will receive a combination of upfront, milestone and royalty payments. Financial details of the agreement were not disclosed.
Testim is currently approved for sale in 15 countries in Europe. Auxilium and Ipsen Pharma recently agreed to mutually terminate their distribution agreement for Testim in Europe and other countries outside North America and Japan.
Testim is a novel, topical gel formulation that normalizes low levels of testosterone in men with hypogonadism, a condition that occurs when a man’s body does not produce adequate amounts of testosterone.
Armando Anido, CEO and president of Auxilium, said: This agreement enables us to bring our new testosterone replacement product to patients in all of the 15 countries where Testim has been approved and potentially in additional new countries within Europe, thus expanding the reach of our Testim franchise outside the US.
Michel Pettigrew, COO of Ferring, said: Testim will be an excellent complement to our urology portfolio, where we already have Minirin for primary nocturnal enuresis and hope to receive approval for our prostate cancer treatment, degarelix, in the first half of 2009.